跳至主要内容
临床试验/EUCTR2020-004966-20-FR
EUCTR2020-004966-20-FR进行中(未招募)1 期

A GLP-1 receptor PET imaging substudy within the VER-AT1D trial investigating the effects on beta cell mass. - PET imaging of beta cells in Type 1 diabetes, effect of verapamil (Image-Ver-A-T1D)

Radboud University Medical Center0 个研究点目标入组 30 人开始时间: 2021年10月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are included in the Ver-A-T1D trial, but have not started treatment/placebo.
  • Have given written informed consent.
  • Age =18 years at consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • (additional to Ver-A-T1D):
  • -Treatment with synthetic exendin (Exentide, Byetta®) or dipeptidyl-peptidase IV inhibitors (to exclude interferences with imaging), specifically mentioned although in principle part of exclusion criteria Ver-A-T1D.
  • - Renal disease defined as MDRD < 40 ml/min/1.73m2
  • - Pregnancy or the wish to become pregnant within 2 month after the second PET/CT scan.

研究者

相似试验

A PET imaging substudy within the VER-AT1D trial... | 临床试验